Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its Rare Disease Portfolio

Shots:

• Ipsen to acquire Clementia Pharmaceuticals in all stock transaction, with its lead candidate palovarotene, for $25/share making the total deal value of $1.04B
• In H2’19, Ipsen plans to file NDA to the US FDA for Palovarotene if approved, Ipsen will pay regulatory milestone as contingent value right (CVR) at $6/share totaling $263M milestone
• Palovarotene is retinoic acid receptor gamma (RARγ) agonist used for fibrodyspasia ossificans progressiva (FOP), multiple osteochondromas (MO) and has received EMA’s ODD and FDA’s FT, BT and Rare Pediatric Disease designation, with its expected approval in 202

Click here to read full press release/ article | Ref: Ipsen | Image: Post Online Media